List of Excipients in Branded Drug BUPROPION HYDROBROMIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oceanside Pharmaceuticals	BUPROPION HYDROBROMIDE	bupropion hydrobromide	68682-580	CARNAUBA WAX	2026-06-27
Oceanside Pharmaceuticals	BUPROPION HYDROBROMIDE	bupropion hydrobromide	68682-580	CROSPOVIDONE	2026-06-27
Oceanside Pharmaceuticals	BUPROPION HYDROBROMIDE	bupropion hydrobromide	68682-580	DIBUTYL SEBACATE	2026-06-27

Bupropion Hydrobromide Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

Bupropion hydrobromide is an approved extended-release salt marketed in the United States as Aplenzin. Its commercial value is concentrated in once-daily modified-release products, differentiated dosage strengths, supply-chain control, and potential generic or 505(b)(2) development. The core formulation challenge is controlling bupropion release while avoiding dose dumping, excessive peak concentrations, and variability that could increase seizure risk.

What is bupropion hydrobromide and how is it commercialized?

Bupropion hydrobromide is the hydrobromide salt of the aminoketone antidepressant bupropion. It has the same active moiety as bupropion hydrochloride products such as Wellbutrin, Wellbutrin XL, and Zyban, but it is a different pharmaceutical salt.

Aplenzin is an extended-release tablet approved for major depressive disorder and seasonal affective disorder. The product is administered once daily and is available in three strengths:

Product strength	Bupropion hydrobromide content	Approximate bupropion active-moiety equivalent
Aplenzin 174 mg	174 mg	150 mg
Aplenzin 348 mg	348 mg	300 mg
Aplenzin 522 mg	522 mg	450 mg

The salt contains more mass per unit of active bupropion than bupropion hydrochloride. This affects tablet size, excipient loading, dose uniformity, and the design space for high-strength products. The FDA label identifies Aplenzin as an extended-release tablet that must be swallowed whole and must not be crushed, divided, or chewed because altered release can increase adverse-event risk (FDA, 2023a).

What excipients are used in bupropion hydrobromide extended-release tablets?

The Aplenzin formulation uses a conventional matrix-and-coating approach. Public labeling identifies excipient classes that include a release-controlling polymer, binders, fillers, lubricants, glidants, and film-coating materials (FDA, 2023a).

Formulation function	Publicly identified or commercially relevant excipient classes
Matrix or release control	Ethylcellulose, hypromellose
Filler and compression aid	Microcrystalline cellulose
Binder	Povidone
Lubricant	Magnesium stearate
Hydrophobic release modifier	Glyceryl behenate
Glidant or processing aid	Colloidal silicon dioxide
Surfactant or wetting aid	Sodium lauryl sulfate
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, colorants

The formulation is commercially attractive because it relies on widely available excipients rather than a highly specialized delivery platform. That reduces technical barriers for a generic developer. The difficulty lies in reproducing the complete release profile and pharmacokinetic behavior, not merely matching the ingredient list.

Which excipient attributes matter most?

The most important excipient attributes are polymer viscosity, particle-size distribution, moisture content, compressibility, lubricant level, and hydrophobicity. Small changes can affect dissolution and tablet robustness.

Ethylcellulose and hypromellose can control water penetration and drug diffusion. Glyceryl behenate can add hydrophobic resistance and improve sustained-release behavior. Microcrystalline cellulose supports tablet strength but can also affect porosity and liquid ingress. Magnesium stearate requires tight control because over-lubrication can reduce tablet wetting and slow release.

A developer should characterize:

• Polymer substitution level and viscosity grade
• Excipient particle size and bulk density
• Granule porosity and tablet tensile strength
• Water activity and residual moisture
• Lubrication time and lubricant concentration
• Coating weight gain and film permeability
• Dissolution under multiple pH and agitation conditions

What is the best excipient strategy for a generic bupropion hydrobromide product?

The most defensible strategy is a quality-by-design program that treats dissolution as a multidimensional target rather than a single specification. A developer should establish a formulation map around polymer level, polymer ratio, tablet hardness, porosity, lubricant concentration, and coating permeability.

Matrix-tablet strategy

A hydrophilic-hydrophobic matrix is the lowest-risk platform for a conventional generic. It has established manufacturing processes, readily sourced materials, and a comparatively simple regulatory narrative.

Its weaknesses are scale sensitivity and sensitivity to compression force. A change in granulation or tablet hardness can alter release. High-dose tablets also create challenges in tablet size, swallowability, and mechanical strength.

Film-coated matrix strategy

A film-coated matrix can provide additional control over initial release, moisture protection, appearance, and handling. The coating should not be treated as cosmetic. Polymer permeability, coating thickness, curing, and storage humidity can materially affect dissolution.

This approach creates an opportunity for excipient suppliers that can provide low-variability hypromellose, ethylcellulose dispersions, and validated coating systems.

Multiparticulate strategy

Multiparticulates, coated pellets, or mini-tablets could provide a more flexible release profile and reduce sensitivity to a single tablet geometry. They may also support sprinkle formulations or alternative administration formats.

The main drawbacks are higher manufacturing complexity, greater analytical burden, and potential regulatory friction if the dosage form differs materially from the reference product. The commercial opportunity is stronger for a differentiated 505(b)(2) product than for a straightforward ANDA.

Osmotic or proprietary delivery system

An osmotic system could provide a differentiated release mechanism, but bupropion hydrobromide already has an approved once-daily product. The additional development cost would need to be justified by a clear clinical or commercial benefit, such as lower peak exposure, improved tolerability, or a new administration route.

What FDA regulatory pathway applies to bupropion hydrobromide?

A generic version of Aplenzin would generally be pursued through an ANDA if the applicant can demonstrate pharmaceutical equivalence, bioequivalence, and conformity with the reference product’s dosage form and labeling requirements. The relevant reference product is bupropion hydrobromide extended-release, not simply any bupropion hydrochloride product.

Bupropion hydrochloride products cannot automatically establish equivalence to bupropion hydrobromide products because the salts differ chemically. A developer using bupropion hydrochloride would likely face a different regulatory pathway, potentially including a 505(b)(2) application, depending on the proposed product and the FDA’s determination.

The FDA has published bioequivalence guidance for extended-release bupropion products because release-rate differences can affect clinical performance (FDA, 2018). The agency has also taken enforcement action against products that failed to demonstrate comparable release and pharmacokinetic behavior to reference bupropion products (FDA, 2012).

When does bupropion hydrobromide lose exclusivity?

Aplenzin received FDA approval in 2008. FDA drug exclusivity generally expires after the applicable statutory period, but patent protection and regulatory exclusivity must be analyzed separately. Commercial generic entry depends on the Orange Book patent listing, litigation, paragraph IV certifications, settlements, and the timing of final ANDA approval.

Exclusivity category	Strategic relevance
New chemical entity exclusivity	Bupropion was previously approved in other salt forms, so the hydrobromide product’s regulatory exclusivity analysis is distinct from first approval of bupropion
Formulation patents	May protect extended-release architecture, polymer systems, or dosage forms
Method-of-use patents	May cover depression or seasonal affective disorder indications
Orange Book listing	Determines patent certifications required in an ANDA
Paragraph IV litigation	Can delay approval for up to 30 months after suit, subject to statutory conditions
Pediatric exclusivity	Can extend qualifying listed patents or exclusivity by six months

The exact current Orange Book patent position for Aplenzin should be assessed against the FDA’s live product and patent datasets rather than inferred from historical approvals. A fixed expiration date without a current Orange Book review would not be reliable.

What patent protection covers bupropion hydrobromide?

The relevant patent categories are likely to include:

1. The hydrobromide salt itself or salt preparation.
2. Extended-release compositions.
3. Polymer-controlled dissolution profiles.
4. Dosage strengths and once-daily administration.
5. Treatment of major depressive disorder or seasonal affective disorder.
6. Manufacturing processes and solid-state properties.

A patent covering bupropion hydrochloride extended release does not necessarily cover bupropion hydrobromide. Conversely, a patent directed specifically to the hydrobromide salt may have limited scope if it does not claim a formulation, method, or commercially relevant dosage form.

Patent strength depends on claim construction, priority dates, prosecution history, written description, enablement, and the ability to distinguish earlier bupropion salt and formulation disclosures. Formulation claims based only on routine polymer selection may face greater validity pressure than claims tied to a defined dissolution profile, pharmacokinetic parameter, or unexpected stability result.

Which companies could challenge bupropion hydrobromide exclusivity?

Potential challengers include large generic manufacturers with experience in modified-release central nervous system products, specialty generic companies, and contract development organizations that already manufacture bupropion tablets.

The main competitive groups are:

Competitor type	Likely strategy
Large generic manufacturers	ANDA for a compositionally similar extended-release tablet
Specialty generics	505(b)(2) product with differentiated dosing or administration
Excipient and formulation companies	Platform licensing, coating systems, or development partnerships
Branded CNS companies	Reformulated bupropion product or fixed-dose combination
Contract manufacturers	Technology transfer and commercial-scale supply

The most credible generic challenge would use the same salt, a conventional extended-release matrix, and a bioequivalence program designed around multiple strengths. A differentiated product would require stronger clinical or patient-use justification.

What commercial opportunities exist for excipient suppliers?

The largest opportunity is not a new excipient. It is a validated excipient system that reduces batch variability and supports regulatory comparability.

High-value opportunities

• Low-variability hypromellose grades for extended-release matrices
• Ethylcellulose systems with predictable permeability
• Direct-compression excipient blends for high-dose tablets
• Low-moisture grades that improve stability
• Coating systems that control water ingress and initial release
• Functional excipients that improve tablet strength without slowing dissolution excessively
• Dual-source formulations that reduce dependence on a single supplier
• Continuous-manufacturing excipient packages with narrow material-property ranges

Excipient suppliers can create commercial differentiation through design-space data, not only material identity. Useful data packages include dissolution sensitivity studies, compatibility data, scale-up performance, and stability under high humidity.

How does bupropion hydrobromide compare with bupropion hydrochloride?

Attribute	Bupropion hydrobromide	Bupropion hydrochloride
Active moiety	Bupropion	Bupropion
Salt	Hydrobromide	Hydrochloride
Approved products	Aplenzin	Wellbutrin, Wellbutrin XL, Zyban and generics
Key commercial form	Extended-release tablet	Immediate-, sustained-, and extended-release products
Generic substitution	Not automatically interchangeable across salts	Established generic market
Excipient opportunity	Salt-specific extended-release development	Larger existing generic base
Regulatory risk	Demonstrating equivalence to hydrobromide reference	Release-profile and product-specific equivalence

Bupropion hydrochloride has the larger market and deeper generic manufacturing base. Bupropion hydrobromide offers a narrower but potentially less crowded opportunity, particularly if a developer can secure a reliable source of the active pharmaceutical ingredient and reproduce the reference dissolution profile.

What generic launch scenarios are most plausible?

The most likely launch scenario is a conventional extended-release tablet using the same active salt and a functionally similar excipient architecture. This approach minimizes clinical and regulatory risk.

A second scenario is a limited-strength launch focused on the 348 mg product, followed by additional strengths after manufacturing and bioequivalence experience is established. The 522 mg strength may carry higher technical risk because of tablet mass, dose uniformity, and release control.

A third scenario is a 505(b)(2) product with a new dosage form, lower-frequency administration, modified titration, or an alternative administration feature. That pathway offers more differentiation but carries greater development cost and patent exposure.

What manufacturing and IP barriers affect commercialization?

The principal manufacturing barriers are:

• Consistent high-dose tablet compression
• Control of polymer distribution throughout the tablet
• Prevention of dose dumping after mechanical damage
• Reproducible dissolution across commercial-scale batches
• Control of moisture and coating permeability
• Reliable supply of pharmaceutical-grade bupropion hydrobromide
• Demonstration that post-approval process changes do not alter release

The principal IP barriers are product-specific patent claims, formulation patents, method-of-use patents, and litigation triggered by paragraph IV certification. A generic developer also must evaluate non-Orange Book patents, trade secrets relating to manufacturing, and supplier exclusivity arrangements.

Key Takeaways

• Bupropion hydrobromide is commercially established through Aplenzin extended-release tablets.
• The strongest formulation opportunity is a robust matrix or film-coated matrix system using controlled-grade hypromellose and ethylcellulose.
• Excipient selection should focus on material-property control, dissolution reproducibility, and scale-up performance.
• Bupropion hydrochloride products cannot be treated as automatic substitutes for bupropion hydrobromide products.
• The generic opportunity is narrower than for bupropion hydrochloride but may face less direct competition.
• A conventional ANDA is the lowest-risk commercial route; a 505(b)(2) product requires a stronger differentiation case.
• Current Orange Book patents, litigation, and exclusivity status must be reviewed before assigning a definitive generic-entry date.

FAQs

Is bupropion hydrobromide the same as bupropion hydrochloride?

No. Both contain bupropion as the active moiety, but they are different salts with different molecular weights and product-specific regulatory requirements.

Can bupropion hydrobromide be formulated with the same excipients as Wellbutrin XL?

Potentially, but the formulation cannot be copied solely on the basis of excipient identity. Salt properties, tablet density, polymer loading, dissolution, and bioequivalence must be established independently.

Is Aplenzin an immediate-release or extended-release product?

Aplenzin is an extended-release tablet administered once daily.

What is the main technical risk in developing a generic bupropion hydrobromide tablet?

The main risk is failure to reproduce the reference product’s release and pharmacokinetic profile across strengths and manufacturing scales.

Is there a major biosimilar opportunity for bupropion hydrobromide?

No. Bupropion hydrobromide is a small-molecule drug, so the relevant competition is generic or 505(b)(2) competition, not biosimilar competition.

References

1. U.S. Food and Drug Administration. (2012). FDA alerts health care professionals about the results of a study of bupropion hydrochloride extended-release tablets.
2. U.S. Food and Drug Administration. (2018). Bupropion hydrochloride extended-release tablets: Product-specific guidance for industry.
3. U.S. Food and Drug Administration. (2023a). Aplenzin: Prescribing information.
4. U.S. Food and Drug Administration. (2023b). Orange Book: Approved drug products with therapeutic equivalence evaluations.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs.